KMDA

Kamada Ltd

Stock NASDAQ – Stock Market Prices, News & Analysis

Kamada Ltd is a biopharmaceutical company specializing in the development, production, and marketing of specialty therapies for rare and serious diseases.

$ 8.21
1.79 %

Kamada Ltd

$ 8.21
1.79 %
KMDA

Kamada Ltd is a biopharmaceutical company specializing in the development, production, and marketing of specialty therapies for rare and serious diseases.

Price history of Kamada Ltd
Price history of Kamada Ltd

Performance & Momentum

6 Months 23.49 %
1 Year 28.55 %
3 Years 92.93 %
5 Years 43.82 %

Strategic Analysis

Kamada Ltd • 2026

Kamada Ltd positions itself as a specialist in biotherapies targeting rare and severe diseases, which limits direct competition thanks to a model deeply rooted in the orphan drug niche. Its expertise in integrated development, manufacturing, and commercialization gives it the ability to control quality and the value chain, supporting a strong international footprint.

Strengths
  • Strong specialization in treatments for rare diseases, a segment with high barriers to entry
  • Integrated model covering R&D, manufacturing and commercialization, ensuring operational control
  • Sustained long-term stock performance, reflecting investor confidence in its potential
Weaknesses
  • Dependence on niche markets limiting revenue diversification
  • Exposure to regulatory risks specific to innovative biopharmaceutical products
Momentum

Current momentum is solid and reflects growing investor interest supported by a favorable performance trajectory over several years. The absence of recent news calls for close monitoring of pipeline progress and strategic communication to confirm this momentum.

Similar stocks to Kamada Ltd

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone